Suren G. Dutia - 12 Nov 2026 Form 4 Insider Report for CITIUS ONCOLOGY, INC. (CTOR)

Reporting relationship: Director
Issuer ticker: CTOR
Reported as of: 12 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Nov 2026, 16:32:52 UTC
Prior SEC filing: 01 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Alexander M. Donaldson, by Power of Attorney

Filing notes and source

Key filing fact

Suren G. Dutia filed Form 4 for CITIUS ONCOLOGY, INC. (CTOR) on 13 Nov 2026.

Key facts

This page summarizes Suren G. Dutia's Form 4 filing for CITIUS ONCOLOGY, INC. (CTOR).
1 reported transaction and 3 derivative rows are listed below.
Accepted by SEC: 13 Nov 2026, 16:32.

Change

Previous filing in this sequence was filed on 01 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001514063 Primary reporting owner

Dutia Suren G

Relationship: Director
Address: C/O CITIUS ONCOLOGY, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD
Signature: /s/ Alexander M. Donaldson, by Power of Attorney
Signature date: 13 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTOR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 300,000
Date: 12 Nov 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTOR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +125,000
Change %
Price: $0.000000^*
Shares after: 125,000
Date: 12 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $0.5223
Footnotes: F2

CTOR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 125,000
Date: 12 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $1.07
Footnotes: F3

CTOR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 150,000
Date: 12 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $2.15
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

Footnote F2

These options were granted on November 12, 2026. The options vest in full on November 12, 2027, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

Footnote F3

These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

Footnote F4

These options are 100% vested.